The dependency of the growth of tumors on blood vessels, once considered a doubtful
proposition, has become a major avenue of research and drug development. This review …

Several vascular endothelial growth factor (VEGF)-targeted agents, administered either as
single agents or in combination with chemotherapy, have been shown to benefit patients …

Cancer metastasis is responsible for the vast majority of cancer‐related deaths worldwide. In
contrast to numerous discoveries that reveal the detailed mechanisms leading to the …

Abstract CD4+ CD25+ regulatory T cells are involved in the prevention of autoimmune
diseases and in tumor-induced tolerance. We previously demonstrated in tumor-bearing …

Since its inception in 2000, metronomic chemotherapy has undergone major advances as
an antiangiogenic therapy. The discovery of the pro-immune properties of chemotherapy …

Metronomic chemotherapy describes the close, regular administration of chemotherapy
drugs at less-toxic doses over prolonged periods of time. In 2015, the results of randomized …

Increases in the number of circulating endothelial cells (CECs) and progenitors (CEPs) have
been reported in various pathological conditions including cancer. Preclinical studies have …

Although cancer cells are not generally controlled by normal regulatory mechanisms, tumor
growth is highly dependent on the supply of oxygen, nutrients, and host-derived regulators. It …

Angiogenesis is a hallmark of tumor development and metastasis and is now a validated
target for cancer treatment. However, the survival benefits of antiangiogenic drugs have thus …

Several hypotheses have been proposed to explain how antiangiogenic drugs enhance the
treatment efficacy of cytotoxic chemotherapy, including impairing the ability of chemotherapy …